Top Biopharma Brands Reach Audiences 10x More Qualified with Veeva Crossix Prime Segments
PLEASANTON, Calif., April 23, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 16 of the top 20 biopharmas are increasing media efficiency with Veeva Crossix Prime Segments, privacy-safe data helping life sciences brands reach highly-qualified health audiences. Since launching in April 2023, Veeva Crossix Prime Segments have helped top biopharmas reach consumers that are 10 times more qualified than standard health audience segments through digital media campaigns.
- Since launching in April 2023, Veeva Crossix Prime Segments have helped top biopharmas reach consumers that are 10 times more qualified than standard health audience segments through digital media campaigns.
- Marketing teams can leverage Veeva Crossix Prime Segments to reach precise patient audiences and Veeva Crossix Reach Segments for broad awareness and ROI at scale.
- "A diverse set of health brands are using Veeva Crossix Prime Segments to reach their most qualified audiences — from broad treatment categories to rare diseases," said Jessica Daigle, head of Veeva Crossix Audience Segments.
- Veeva Crossix Prime Segments are custom-built to reach an advertiser's most qualified audience in a privacy-safe, HIPAA-compliant way.